Please login to the form below

Not currently logged in
Email:
Password:

Alkopharma acquires rights to Navoban

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights.

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights. 

Alkopharma intends to commercialise the drug in more than 80 countries and will drive into new markets, such as the US, to reinforce the company's growing position globally.

Alain Bouaziz, Alkopharma's president and CEO, said the deal marked an exciting step for the company and maintained the ethical basis that the company was founded on 10 years ago.

Alkopharma acquires original molecules from large pharmaceutical companies that are no longer interested in manufacturing drugs from them, such as those used in orphan diseases. In this way, it attempts to meet patients' needs for personalised treatments for rare diseases.

A new manufacturing facility is to be built in Wallis, Switzerland, starting in January 2010, to support the company's R&D and expansion plans. It will house two units, one dedicated to the production of anti-tumour products and the other to biotech-derived products.

11th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics